BN Stock Analysis: Danone | PA
Packaged Foods | PA, France | Market Cap: 47.131m EUR | 12M Return: 10% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 117M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Danone S.A. is a France-based multinational food and beverage company headquartered in Paris, operating across Europe, North America, Asia, Latin America, Africa, the Middle East, and the Commonwealth of Independent States. Founded in 1899 and formerly known as Groupe Danone, the company was renamed in April 2009. It is a constituent of the Consumer Staples sector and is classified in the Packaged Foods & Meats sub-industry, reflecting its positioning as a defensive consumer goods stock with exposure to essential, non-discretionary products.
The business is organized into three segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters. Its product portfolio spans yogurts, dairy items, plant-based alternatives, ice creams, coffee drinks, and cheese under brands such as Activia, Actimel, Alpro, Danone, Oikos, YoPRO, Silk, and So Delicious. The Specialized Nutrition segment targets infants, children, and patients through formulas, complementary feeding, and medical nutrition (e.g., Aptamil, Nutricia, Nutrilon, Neocate, Fortimel), while the Waters segment markets natural mineral waters and flavored beverages including evian, Volvic, AQUA, Bonafont, and Mizone.
Danone distributes through retail chains, traditional outlets, convenience stores, hotels and restaurants, hospitals and pharmacies, and e-commerce platforms. The diversified, health-oriented portfolio - particularly the weighting toward dairy, plant-based, and medical nutrition - illustrates the companys focus on premium, wellness-driven categories, which have historically supported more stable margins and recurring demand relative to the broader packaged foods industry.
- China infant formula revenue pressured by declining birth rate
- Evian and Volvic bottled water volumes face demand headwinds
- Specialized Nutrition margins expand on premium product mix
| Net Income: 1.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.38 > 1.0 |
| NWC/Revenue: -5.12% < 20% (prev -3.46%; Δ -1.66% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.78b > Net Income 1.82b |
| Net Debt (9.48b) to EBITDA (4.39b): 2.16 < 3 |
| Current Ratio: 0.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (645.1m) vs 12m ago 0.51% < -2% |
| Gross Margin: 50.62% > 18% (prev 49.70%; Δ 0.91% > 0.5%) |
| Asset Turnover: 60.39% > 50% (prev 60.44%; Δ -0.06% > 0%) |
| Interest Coverage Ratio: 6.09 > 6 (EBIT TTM 3.03b / Interest Expense TTM 498.0m) |
| A: -0.03 (Total Current Assets 13.2b - Total Current Liabilities 14.6b) / Total Assets 45.1b |
| B: 0.41 (Retained Earnings 18.6b / Total Assets 45.1b) |
| C: 0.07 (EBIT TTM 3.03b / Avg Total Assets 45.2b) |
| D: 0.60 (Book Value of Equity 16.9b / Total Liabilities 28.1b) |
| Altman-Z'' = 2.22 = BBB |
| DSRI: 1.04 (Receivables 3.04b/2.92b, Revenue 27.3b/27.4b) |
| GMI: 0.98 (GM 49.70% / 50.62%) |
| AQI: 0.98 (AQ_t 0.56 / AQ_t-1 0.57) |
| SGI: 1.00 (Revenue 27.3b / 27.4b) |
| TATA: -0.04 (NI 1.82b - CFO 3.78b) / TA 45.1b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 13, 2026, the stock is trading at EUR 72.42 with a total of 946,400 shares traded. Over the past week, the price has changed by -1.34%, over one month by +7.80%, over three months by +11.42% and over the past year by +9.95%.
Current recommended Stop Loss: 70.70 (which is 2.4% or 1.3 ATR below the current price).
Danone has no consensus analysts rating.
P/E Trailing = 26.0284
P/E Forward = 19.1205
P/S = 1.7275
P/B = 2.8073
P/EG = 1.8578
Revenue TTM = 27.3b EUR
EBIT TTM = 3.03b EUR
EBITDA TTM = 4.39b EUR
Long Term Debt = 9.76b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.04b EUR (from shortTermDebt, last quarter)
Debt = 16.1b EUR (from shortLongTermDebtTotal, last quarter) + Leases 937.0m
Net Debt = 9.48b EUR (calculated: Debt 16.1b - CCE 6.57b)
Enterprise Value = 56.6b EUR (47.1b + Debt 16.1b - CCE 6.57b)
Interest Coverage Ratio = 6.09 (Ebit TTM 3.03b / Interest Expense TTM 498.0m)
EV/FCF = 20.78x (Enterprise Value 56.6b / FCF TTM 2.72b)
FCF Yield = 4.81% (FCF TTM 2.72b / Enterprise Value 56.6b)
FCF Margin = 9.98% (FCF TTM 2.72b / Revenue TTM 27.3b)
Net Margin = 6.69% (Net Income TTM 1.82b / Revenue TTM 27.3b)
Gross Margin = 50.62% ((Revenue TTM 27.3b - Cost of Revenue TTM 13.5b) / Revenue TTM)
Gross Margin QoQ = 50.33% (prev 50.90%)
Tobins Q-Ratio = 1.26 (Enterprise Value 56.6b / Total Assets 45.1b)
Interest Expense / Debt = 3.10% (Interest Expense 498.0m / Debt 16.1b)
Taxrate = 29.22% (741.0m / 2.54b)
NOPAT = 2.15b (EBIT 3.03b * (1 - 29.22%))
Current Ratio = 0.90 (Total Current Assets 13.2b / Total Current Liabilities 14.6b)
Debt / Equity = 0.95 (Debt 16.1b / totalStockholderEquity, last quarter 16.9b)
Debt / EBITDA = 2.16 (Net Debt 9.48b / EBITDA 4.39b)
Debt / FCF = 3.48 (Net Debt 9.48b / FCF TTM 2.72b)
Total Stockholder Equity = 16.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 1.82b / Total Assets 45.1b)
RoE = 10.84% (Net Income TTM 1.82b / Total Stockholder Equity 16.8b)
RoCE = 11.41% (EBIT 3.03b / Capital Employed (Equity 16.8b + L.T.Debt 9.76b))
RoIC = 6.29% (NOPAT 2.15b / Invested Capital 34.1b)
WACC = 4.11% (E(47.1b)/V(63.2b) * Re(4.76%) + D(16.1b)/V(63.2b) * Rd(3.10%) * (1-Tc(0.29)))
Discount Rate = 4.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 0.27%
[DCF] Terminal Value 74.54% ; FCFF base≈2.80b ; Y1≈2.66b ; Y5≈2.53b
[DCF] Fair Price = 47.18 (EV 39.8b - Net Debt 9.48b = Equity 30.3b / Shares 642.1m; r=8.35% [WACC [floored]]; 5y FCF grow -6.33% → 2.50% )
EPS Correlation: 34.75 | EPS CAGR: 20.37% | SUE: N/A | # QB: 0
Revenue Correlation: 63.76 | Revenue CAGR: 8.77% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.90 | Chg30d=+0.21% | Revisions=+30% | GrowthEPS=+2.8% | GrowthRev=+3.0%
EPS next Year (2027-12-31): EPS=4.22 | Chg30d=+0.83% | Revisions=+22% | GrowthEPS=+8.2% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +31% (up=9, down=4)